SCHEMBL21885975

SCHEMBL21885975

CC(C)NS(=O)(=O)c1ccc(Cl)cn1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.43
CHRM1 P11229 1/20 0.43
RRM1 P23921 1/20 0.43
RRM2B Q7LG56 1/20 0.43
POLB P06746 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ALDH1A1 P00352 5/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
TSHR P16473 2/20 0.39
PTK2 Q05397 1/20 0.38
EDNRA P25101 1/20 0.37
KDM4E B2RXH2 1/20 0.37
LMNA P02545 1/20 0.37
HSD17B10 Q99714 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
GRIA2 P42262 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7912693 0.81 SLC40A1 (0.47) KMT2AALDH1A1SMN1; SMN2TSHREDNRA
SCHEMBL427939 0.80 CA12 (0.52) POLBMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL25825555 0.79 EDNRA (0.42) ALDH1A1SMN1; SMN2TSHREDNRAKDM4E
SCHEMBL758126 0.79 CA12 (0.55) MEN1KMT2AALDH1A1SMN1; SMN2TSHR
SCHEMBL21633890 0.77 POLB (0.44) POLBMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL2646778 0.77 POLB (0.41) POLBMEN1KMT2ASMN1; SMN2TSHR
SCHEMBL24549598 0.76 ALDH1A1 (0.51) POLBMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL2645976 0.74 NFE2L2 (0.41) POLBMEN1KMT2APTK2KDM4E
SCHEMBL18571397 0.72 KDM4E (0.44) POLBMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL7909439 0.72 CA2 (0.61) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230165854-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY SHOUTI INC. 2023-06-01 US disclosed
US-20220194945-A1 Imidazolopyridine Compounds For IRE1 Inhibition Optikira, LLC 2022-06-23 US disclosed
WO-2020073011-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY ANNAPURNA BIO, INC. (US) 2020-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220194945-A1 Imidazolopyridine Compounds For IRE1 Inhibition XBP1, ERN2, ERN1 CHRM2 4471/4885CHRM1 4459/4885RRM1 2678/4885
US-20230165854-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY APLNR, AGTR1, AGTR2 CHRM2 3016/4885CHRM1 3670/4885RRM1 1829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.